Andrew M. Skinner , Xing Tan , Colin Westman , Thomas Birris , Emily N. Drwiega , Michael S. Wang , Stuart Johnson
{"title":"贝佐托单抗预防多次复发性艰难梭菌感染(CDI)患者复发的疗效。","authors":"Andrew M. Skinner , Xing Tan , Colin Westman , Thomas Birris , Emily N. Drwiega , Michael S. Wang , Stuart Johnson","doi":"10.1016/j.anaerobe.2023.102788","DOIUrl":null,"url":null,"abstract":"<div><p>Among 23 patients with multiply recurrent <em>Clostridiodies difficile</em><span> infection (mrCDI) who received bezlotoxumab<span> at the end of antibiotic treatment a sustained clinical response of 91 % at 30 days and 78 % at 90 days was achieved. Bezlotoxumab administered at the end of antibiotic treatment was effective in patients with mrCDI.</span></span></p></div>","PeriodicalId":8050,"journal":{"name":"Anaerobe","volume":"84 ","pages":"Article 102788"},"PeriodicalIF":2.5000,"publicationDate":"2023-11-04","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"Efficacy of bezlotoxumab to prevent recurrent Clostridioides difficile infection (CDI) in patients with multiple prior recurrent CDI\",\"authors\":\"Andrew M. Skinner , Xing Tan , Colin Westman , Thomas Birris , Emily N. Drwiega , Michael S. Wang , Stuart Johnson\",\"doi\":\"10.1016/j.anaerobe.2023.102788\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<div><p>Among 23 patients with multiply recurrent <em>Clostridiodies difficile</em><span> infection (mrCDI) who received bezlotoxumab<span> at the end of antibiotic treatment a sustained clinical response of 91 % at 30 days and 78 % at 90 days was achieved. Bezlotoxumab administered at the end of antibiotic treatment was effective in patients with mrCDI.</span></span></p></div>\",\"PeriodicalId\":8050,\"journal\":{\"name\":\"Anaerobe\",\"volume\":\"84 \",\"pages\":\"Article 102788\"},\"PeriodicalIF\":2.5000,\"publicationDate\":\"2023-11-04\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Anaerobe\",\"FirstCategoryId\":\"99\",\"ListUrlMain\":\"https://www.sciencedirect.com/science/article/pii/S1075996423000975\",\"RegionNum\":3,\"RegionCategory\":\"生物学\",\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q3\",\"JCRName\":\"MICROBIOLOGY\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Anaerobe","FirstCategoryId":"99","ListUrlMain":"https://www.sciencedirect.com/science/article/pii/S1075996423000975","RegionNum":3,"RegionCategory":"生物学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q3","JCRName":"MICROBIOLOGY","Score":null,"Total":0}
Efficacy of bezlotoxumab to prevent recurrent Clostridioides difficile infection (CDI) in patients with multiple prior recurrent CDI
Among 23 patients with multiply recurrent Clostridiodies difficile infection (mrCDI) who received bezlotoxumab at the end of antibiotic treatment a sustained clinical response of 91 % at 30 days and 78 % at 90 days was achieved. Bezlotoxumab administered at the end of antibiotic treatment was effective in patients with mrCDI.
期刊介绍:
Anaerobe is essential reading for those who wish to remain at the forefront of discoveries relating to life processes of strictly anaerobes. The journal is multi-disciplinary, and provides a unique forum for those investigating anaerobic organisms that cause infections in humans and animals, as well as anaerobes that play roles in microbiomes or environmental processes.
Anaerobe publishes reviews, mini reviews, original research articles, notes and case reports. Relevant topics fall into the broad categories of anaerobes in human and animal diseases, anaerobes in the microbiome, anaerobes in the environment, diagnosis of anaerobes in clinical microbiology laboratories, molecular biology, genetics, pathogenesis, toxins and antibiotic susceptibility of anaerobic bacteria.